Final Results of a Phase 2 Multicenter Study of Ublituximab, a Novel Glycoengineered Anti-CD20 Monoclonal Antibody, in Patients with RMS-MedSci.cn

Final Results of a Phase 2 Multicenter Study of Ublituximab, a Novel Glycoengineered Anti-CD20 Monoclonal Antibody, in Patients with RMS

Fox, EJ; Lovett-Racke, A; Gormley, M; Liu, Y; Petracca, M; Inglese, M; Cocozza, S; Wray, S; Shubin, R; Bosco, JA; Power, SA; Weiss, M; Mok, K; Eubanks, JL

MULTIPLE SCLEROSIS JOURNAL, 2019; 25 (): 49

科室
- - 订阅+
  - 更多科室
工具
服务